A Review of Small-Molecule Epidermal Growth Factor Receptor-Specific Tyrosine Kinase Inhibitors in Development for Non-Small Cell Lung Cancer

Katrina Y. Glover, Roman Perez-Soler, Vassiliki A. Papadimitradopoulou

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Overexpression of the epidermal growth factor receptor is commonly seen in a variety of epithelial tumors including lung cancer, and it is particularly common in the non-small cell histologic variant. Despite intense research efforts, therapeutic advances to date have failed to result in a significant survival benefit for patients with advanced disease. The lack of overall survival benefit and high toxicity associated with cytotoxic chemotherapy indicates the need for novel therapies that have a favorable effect on survival with minimal toxicity. Greater understanding of molecular biology and the intricate cellular pathways has resulted in the development of a new field of targeted therapeutics that will arrest dysregulated cell growth in malignant cells. Tyrosine kinases represent an important category of signaling proteins that catalyze phosphorylation of tyrosine residues leading to reactions ultimately resulting in cell growth, differentiation, proliferation, and death. Inhibition of tyrosine kinase activity represents a logical targeted approach in malignancies with overexpression of tyrosine kinase. Several small-molecule epidermal growth factor receptor tyrosine kinase inhibitors have been developed and are currently undergoing clinical trials. This article will review several of these agents as well as their role in the treatment of non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)83-92
Number of pages10
JournalSeminars in Oncology
Volume31
Issue number1 SUPPL. 1
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Survival
Therapeutic Human Experimentation
Growth
Tyrosine
Molecular Biology
Cell Differentiation
Lung Neoplasms
Neoplasms
Therapeutics
Phosphorylation
Clinical Trials
Drug Therapy
Proteins

ASJC Scopus subject areas

  • Oncology

Cite this

A Review of Small-Molecule Epidermal Growth Factor Receptor-Specific Tyrosine Kinase Inhibitors in Development for Non-Small Cell Lung Cancer. / Glover, Katrina Y.; Perez-Soler, Roman; Papadimitradopoulou, Vassiliki A.

In: Seminars in Oncology, Vol. 31, No. 1 SUPPL. 1, 02.2004, p. 83-92.

Research output: Contribution to journalArticle

@article{f922565d7fae49e3acb7651b44913530,
title = "A Review of Small-Molecule Epidermal Growth Factor Receptor-Specific Tyrosine Kinase Inhibitors in Development for Non-Small Cell Lung Cancer",
abstract = "Overexpression of the epidermal growth factor receptor is commonly seen in a variety of epithelial tumors including lung cancer, and it is particularly common in the non-small cell histologic variant. Despite intense research efforts, therapeutic advances to date have failed to result in a significant survival benefit for patients with advanced disease. The lack of overall survival benefit and high toxicity associated with cytotoxic chemotherapy indicates the need for novel therapies that have a favorable effect on survival with minimal toxicity. Greater understanding of molecular biology and the intricate cellular pathways has resulted in the development of a new field of targeted therapeutics that will arrest dysregulated cell growth in malignant cells. Tyrosine kinases represent an important category of signaling proteins that catalyze phosphorylation of tyrosine residues leading to reactions ultimately resulting in cell growth, differentiation, proliferation, and death. Inhibition of tyrosine kinase activity represents a logical targeted approach in malignancies with overexpression of tyrosine kinase. Several small-molecule epidermal growth factor receptor tyrosine kinase inhibitors have been developed and are currently undergoing clinical trials. This article will review several of these agents as well as their role in the treatment of non-small cell lung cancer.",
author = "Glover, {Katrina Y.} and Roman Perez-Soler and Papadimitradopoulou, {Vassiliki A.}",
year = "2004",
month = "2",
doi = "10.1053/j.seminoncol.2003.11.005",
language = "English (US)",
volume = "31",
pages = "83--92",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - A Review of Small-Molecule Epidermal Growth Factor Receptor-Specific Tyrosine Kinase Inhibitors in Development for Non-Small Cell Lung Cancer

AU - Glover, Katrina Y.

AU - Perez-Soler, Roman

AU - Papadimitradopoulou, Vassiliki A.

PY - 2004/2

Y1 - 2004/2

N2 - Overexpression of the epidermal growth factor receptor is commonly seen in a variety of epithelial tumors including lung cancer, and it is particularly common in the non-small cell histologic variant. Despite intense research efforts, therapeutic advances to date have failed to result in a significant survival benefit for patients with advanced disease. The lack of overall survival benefit and high toxicity associated with cytotoxic chemotherapy indicates the need for novel therapies that have a favorable effect on survival with minimal toxicity. Greater understanding of molecular biology and the intricate cellular pathways has resulted in the development of a new field of targeted therapeutics that will arrest dysregulated cell growth in malignant cells. Tyrosine kinases represent an important category of signaling proteins that catalyze phosphorylation of tyrosine residues leading to reactions ultimately resulting in cell growth, differentiation, proliferation, and death. Inhibition of tyrosine kinase activity represents a logical targeted approach in malignancies with overexpression of tyrosine kinase. Several small-molecule epidermal growth factor receptor tyrosine kinase inhibitors have been developed and are currently undergoing clinical trials. This article will review several of these agents as well as their role in the treatment of non-small cell lung cancer.

AB - Overexpression of the epidermal growth factor receptor is commonly seen in a variety of epithelial tumors including lung cancer, and it is particularly common in the non-small cell histologic variant. Despite intense research efforts, therapeutic advances to date have failed to result in a significant survival benefit for patients with advanced disease. The lack of overall survival benefit and high toxicity associated with cytotoxic chemotherapy indicates the need for novel therapies that have a favorable effect on survival with minimal toxicity. Greater understanding of molecular biology and the intricate cellular pathways has resulted in the development of a new field of targeted therapeutics that will arrest dysregulated cell growth in malignant cells. Tyrosine kinases represent an important category of signaling proteins that catalyze phosphorylation of tyrosine residues leading to reactions ultimately resulting in cell growth, differentiation, proliferation, and death. Inhibition of tyrosine kinase activity represents a logical targeted approach in malignancies with overexpression of tyrosine kinase. Several small-molecule epidermal growth factor receptor tyrosine kinase inhibitors have been developed and are currently undergoing clinical trials. This article will review several of these agents as well as their role in the treatment of non-small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=1242318821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242318821&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2003.11.005

DO - 10.1053/j.seminoncol.2003.11.005

M3 - Article

VL - 31

SP - 83

EP - 92

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 1

ER -